Ugly step sister, page-4

Steady on saverio. Firstly Mitchell Glass says that we need further animal trials before we can do six month trials with the larger doses and six months is what we need to show a good response. That is at least twelve months AFTER manufacture of new supplies, probably another three to six months. That only gets us to end of phase 2. You are probably right that the best strategy is to target orphan indications which will get some assistance from the FDA. This is not something with imminent cash flow. I agree that it is exciting.